Lakefront Biotherapeutics NV (LKFT) Stock Price & Analysis
Lakefront Biotherapeutics NV (LKFT) closed at USD 31.4 on Thursday, October 22, 2026, up 2.68% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 30.58; the Oct 22, 2026 session ranged USD 30.55–31.53 on volume of 307,945 shares. Market capitalization is $2.06B, with a 52-week range of USD 25.68–36.24 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.
Also available as compact Markdown for AI agents: nexqual.com/LKFT.md
Key facts (LKFT)
- 1 of 80 tracked superinvestors hold LKFT (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Analysts: Hold (mean 2.67 on a 1–5 scale) (6 analysts), mean target USD 30.42 (range 21.27–44.03).
- Total return with dividends: 1Y -2.0% vs S&P 500 +14.9%; 5Y -38.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-11, EPS estimate USD 0.23, revenue estimate $41.2M.
Superinvestors (SEC 13F-HR, Q2 2026) (LKFT)
1 of 80 tracked investors hold LKFT. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| David Einhorn | Greenlight Capital | 0.37% | $14.5M | Unchanged |
Analysts (LKFT)
Consensus Hold (mean 2.67 on a 1–5 scale), 6 analysts; mean target USD 30.42 (low 21.27, high 44.03).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | RBC Capital | Upgrade | Sector Perform → Outperform | $26 → $45 |
| 2026-08-11 | Morgan Stanley | Target lowered | Equal-Weight | $30 → $26 |
| 2026-08-11 | RBC Capital | Target lowered | Sector Perform | $28 → $26 |
Total return (dividends reinvested) (LKFT)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -2.0% | -38.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -2.0% | -9.2% |
| Volatility (annualized) | 27.9% | 31.2% |
| Max drawdown | -24.7% (Jan 2026→Aug 2026) | -67.5% (Apr 2022→Feb 2025) |
LKFT suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Alfasigma | “Effective January 31, 2024, following the closing of the transaction between us and Alfasigma S.p.A. to transfer the Jyseleca® business to Alfasigma S.p.A., we assigned our rights and obligations under the filgotinib collaboration to Alfasigma S.p.A., except for our right to receive royalties from Gilead on net sales in the Gilead Territory (meaning all countries in the world other than the countries included in t…” |
| Partner | USWM CT | “Following our decision to initiate the wind-down of the cell therapy activities, we have notified USWM of our decision to terminate the Collaboration and Exclusive License Agreement and all ancillary agreements.” |
| Partner | AbbVie (ABBV) | “In this role, he oversaw complex mergers, acquisitions, licensing, and collaborations, including AbbVie's landmark $63 billion acquisition of Allergan PLC and numerous high-profile partnerships with companies such as Boehringer Ingelheim and Genmab.” |
| Partner | Lonza | “As a result, we fully impaired all associated intangible assets (with a total net book value at September 30, 2025 of €131.5 million), consisting of the in-process R&D (€28.2 million related to two CAR-T product candidates, €7.5 million related to our collaboration with Pregene and €2.2 million related to other assets), the exclusive rights related to our exclusivity contract with Lonza (€51.6 million), the upfron…” |
Quoted from the company's 20-F filed Mar 26, 2026.
LKFT analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.23 | $-1.31 | -117.6% | $41.2M | 1 |
| Next quarter (ends Dec 2026) | $-0.17 | $-0.71 | -76.9% | $106.8M | 2 |
| Current fiscal year (ends Dec 2026) | $-0.71 | $-13.24 | -94.6% | $117.2M | 1 |
| Next fiscal year (ends Dec 2027) | $-1.06 | $-1.72 | -38.2% | $84.6M | 2 |
Key Statistics (as of October 23, 2026 at 09:23 UTC)
| Price | USD 31.4 |
|---|---|
| Change | ▲ 2.68% (up) |
| Previous Close | USD 30.58 |
| Open | USD 30.62 |
| Day Range | USD 30.55 – 31.53 |
| 52-Week Range | USD 25.68 – 36.24 |
| Volume | 307,945 shares |
| Market Cap | $2.06B |
| Exchange | NMS |
Technical Analysis (LKFT)
Nexqual's technical model rates LKFT "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64.92 (neutral) |
| vs SMA50 | Above (USD 29.03) |
| MACD | 0.46 (positive) |
Analyst Ratings (LKFT)
Wall Street analysts rate LKFT "Hold" based on 6 analysts, with a mean price target of USD 30.42 (range USD 21.27–44.03), per Nexqual as of October 23, 2026 at 09:23 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 30.42 |
| High Target | USD 44.03 |
| Low Target | USD 21.27 |
| Buy / Hold / Sell | 2 / 3 / 1 |
Earnings (LKFT)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD 0.23 |
| Revenue Estimate | $41.18M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.03 vs est -11.5 ▲ beat |
| 2026-03-31 | USD 0.21 vs est -0.97 ▲ beat |
| 2025-12-31 | USD 12.27 vs est -0.07 ▲ beat |
| 2025-09-30 | USD -0.18 vs est -0.28 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financials & Fundamentals (LKFT)
| Total Revenue | $990.57M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -81.50% |
| Gross Margin | +67.61% |
| Operating Margin | -359.30% |
| Profit Margin | +60.23% |
| ROE | +20.12% |
| Debt / Equity | 0 |
| Current Ratio | 32.84 |
| Total Cash | $2.24B |
| Total Debt | $6.36M |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financial Health Score (LKFT)
Nexqual rates Lakefront Biotherapeutics NV's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:23 UTC.
| Growth | Strong — Revenue +303% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — EUR 2.24B cash vs EUR 6M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -EUR 227M (TTM) |
| Efficiency | Strong — ROE 20%, ROA 9.9% |
Ownership (LKFT)
| Insider Ownership | +25.45% |
|---|---|
| Institutional Ownership | +23.66% |
| Shares Outstanding | 65.48M |
| Float | 461.79M |
| Short % of Float | +8.28% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Leadership (LKFT)
Lakefront Biotherapeutics NV is led by Henry O. Gosebruch, CEO & Executive Director, per Nexqual as of October 23, 2026 at 09:23 UTC.
| CEO & Executive Director | Henry O. Gosebruch |
|---|---|
| Chief Financial Officer | Aaron L. Cox |
| Chief Operating Officer | Christina Carlson |
Major Backers & Investors (LKFT)
Notable institutional backers of Lakefront Biotherapeutics NV include Gilead Sciences Inc, Tang Capital Management, LLC, Madison Avenue Partners, LP, according to Nexqual as of October 23, 2026 at 09:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Gilead Sciences Inc | 25.35% |
| Tang Capital Management, LLC | 5.75% |
| Madison Avenue Partners, LP | 5.23% |
| Prosight Management, Lp | 3.1% |
| EcoR1 Capital, LLC | 2.53% |
| Ameriprise Financial, Inc. | 1.93% |
| DME Capital Management, LP | 0.73% |
| Renaissance Technologies | 0.62% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Columbia Threadneedle | 1.7% |
| BlackRock | 0.51% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BLTE | Belite Bio, Inc | USD 150.27 | ▼ 1.9% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| TGTX | TG Therapeutics, Inc. | USD 53.16 | ▼ 0.08% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt